Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
Current clinical trials for non-Hodgkin's lymphoma (NHL) focus heavily on early-phase development of CAR-T cell therapies and the evaluation of bispecific antibodies.
Yes, adding gemcitabine to cisplatin-based chemotherapy improves survival for muscle-invasive bladder cancer patients, as shown in the NIAGARA trial.
Yes, cisplatin-based chemotherapy is associated with better overall survival than carboplatin for advanced bladder cancer, but carboplatin is used when patients cannot tolerate…
Yes, a cystic mass in renal clear cell carcinoma can shrink on its own, but this is extremely rare and does not replace the need for surgical treatment.
Yes, CIK/DC-CIK cell therapy plus chemotherapy improves overall survival and disease-free survival in gastric cancer patients compared to chemotherapy alone.
Yes, enteral immunonutrition (EIN) reduces infection risks after gastric cancer surgery, with a 52% lower odds of infectious complications compared to standard enteral nutrition…
Yes, DNA damage response inhibitors can help overcome drug resistance in pancreatic cancer, especially when combined with other therapies, but single-agent use has limitations.
Pancreatic cancer risk comes from modifiable factors like smoking, obesity, and heavy drinking, plus inherited mutations in genes such as BRCA1/2 and PALB2.
EGCG shows promise against pancreatic cancer in lab and animal studies, but human trials are lacking, so it is not yet a proven treatment.
Yes, OTUD7B promotes pancreatic cancer growth by stabilizing oncoproteins and activating signaling pathways like Notch and EGFR/MAPK.
Osimertinib is effective for EGFR-mutated NSCLC patients with active brain metastases, with real-world data showing median progression-free survival of 12.4 months and…
Yes, a high neutrophil-to-lymphocyte ratio (NLR) is linked to a higher risk of developing brain metastasis in lung cancer patients, according to a meta-analysis and other studies.
Lung cancer brain metastasis is driven by tumor cells co-opting brain developmental pathways, secreting exosomal CEMIP and LCN2, and recruiting astrocytes and macrophages to…
Yes, stereotactic radiotherapy is an effective treatment for brain metastases, offering high local control rates and preserving cognitive function.
Brain metastases are common in lung cancer, especially small cell (15% at diagnosis) and non-small cell types, with elevated neutrophil-to-lymphocyte ratio as a risk factor…
Yes, a high neutrophil-to-lymphocyte ratio (NLR) is an independent risk factor for brain metastasis in lung cancer, according to a meta-analysis of 14 studies.
Endobronchial access has the lowest inaccurate placement rate and low complication risk, making it a strong choice for fiducial marker insertion before lung cancer radiation.
Datopotamab deruxtecan did not improve overall survival compared to chemotherapy in metastatic HR-positive breast cancer, despite improving progression-free survival.
Yes, trastuzumab deruxtecan improves progression-free survival compared to chemotherapy in HR-positive, HER2-low breast cancer, but overall survival data are not yet mature.
Yes, enzalutamide plus ADT significantly improves survival in metastatic hormone-sensitive prostate cancer, with a 34% reduction in risk of death and a 5-year survival rate of…
Yes, research on macrophage polarization in prostate cancer has grown significantly since 2015, with studies exploring its role in tumor progression and therapy resistance.
Quality of life for colorectal cancer survivors is influenced by physical symptoms, psychological distress, social support, self-efficacy, and demographic factors like age and…
Specific mutations like KRAS, BRAF, and MMR status strongly influence treatment response in colorectal cancer, guiding targeted therapy and immunotherapy decisions.
Yes, home exercise may help reduce fatigue and anxiety in colorectal cancer patients, but the evidence is low certainty and more research is needed.
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.